These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25746108)

  • 1. Modulation of immune responses by histone deacetylase inhibitors.
    Schotterl S; Brennenstuhl H; Naumann U
    Crit Rev Oncog; 2015; 20(1-2):139-54. PubMed ID: 25746108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function.
    Brogdon JL; Xu Y; Szabo SJ; An S; Buxton F; Cohen D; Huang Q
    Blood; 2007 Feb; 109(3):1123-30. PubMed ID: 17008546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection.
    Roger T; Lugrin J; Le Roy D; Goy G; Mombelli M; Koessler T; Ding XC; Chanson AL; Reymond MK; Miconnet I; Schrenzel J; François P; Calandra T
    Blood; 2011 Jan; 117(4):1205-17. PubMed ID: 20956800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
    Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
    J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone Deacetylase Inhibitors Promote Mitochondrial Reactive Oxygen Species Production and Bacterial Clearance by Human Macrophages.
    Ariffin JK; das Gupta K; Kapetanovic R; Iyer A; Reid RC; Fairlie DP; Sweet MJ
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1521-9. PubMed ID: 26711769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y; Seto E
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylases as targets for treatment of multiple diseases.
    Tang J; Yan H; Zhuang S
    Clin Sci (Lond); 2013 Jun; 124(11):651-62. PubMed ID: 23414309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases.
    Gatla HR; Muniraj N; Thevkar P; Yavvari S; Sukhavasi S; Makena MR
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30841513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone Deacetylase Inhibitors Modulating Non-epigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention.
    Ganai SA
    Curr Drug Targets; 2018; 19(6):593-601. PubMed ID: 27231104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors in the treatment of hematological malignancies.
    Petrella A; Fontanella B; Carratù A; Bizzarro V; Rodriquez M; Parente L
    Mini Rev Med Chem; 2011 Jun; 11(6):519-27. PubMed ID: 21561404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Histone Deacetylases in Diseases: Where Are We?
    Benedetti R; Conte M; Altucci L
    Antioxid Redox Signal; 2015 Jul; 23(1):99-126. PubMed ID: 24382114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase (HDACs) inhibitors: Clinical applications.
    Shanmukha KD; Paluvai H; Lomada SK; Gokara M; Kalangi SK
    Prog Mol Biol Transl Sci; 2023; 198():119-152. PubMed ID: 37225317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDAC inhibition and graft versus host disease.
    Choi S; Reddy P
    Mol Med; 2011; 17(5-6):404-16. PubMed ID: 21298214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory effects of histone deacetylase inhibitors.
    Licciardi PV; Ververis K; Tang ML; El-Osta A; Karagiannis TC
    Curr Mol Med; 2013 May; 13(4):640-7. PubMed ID: 23061676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53.
    Mrakovcic M; Bohner L; Hanisch M; Fröhlich LF
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylases as regulators of inflammation and immunity.
    Shakespear MR; Halili MA; Irvine KM; Fairlie DP; Sweet MJ
    Trends Immunol; 2011 Jul; 32(7):335-43. PubMed ID: 21570914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
    Hutt DM; Roth DM; Marchal C; Bouchecareilh M
    Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospects: histone deacetylase inhibitors.
    Dokmanovic M; Marks PA
    J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.
    Minucci S; Pelicci PG
    Nat Rev Cancer; 2006 Jan; 6(1):38-51. PubMed ID: 16397526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.